Your browser doesn't support javascript.
loading
EZH2 regulates oncomiR-200c and EMT markers in esophageal squamous cell carcinomas.
Nourmohammadi, Fatemeh; Forghanifard, Mohammad Mahdi; Abbaszadegan, Mohammad Reza; Zarrinpour, Vajiheh.
Afiliación
  • Nourmohammadi F; Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran.
  • Forghanifard MM; Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran. MM.Forghanifard@iau.ac.ir.
  • Abbaszadegan MR; Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Zarrinpour V; Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran.
Sci Rep ; 12(1): 18290, 2022 10 31.
Article en En | MEDLINE | ID: mdl-36316365
ABSTRACT
EZH2, as a histone methyltransferase, has been associated with cancer development and metastasis possibly through the regulation of microRNAs and cellular pathways such as EMT. In this study, the effect of EZH2 expression on miR-200c and important genes of the EMT pathway was investigated in esophageal squamous cell carcinoma (ESCC). Comparative qRT-PCR was used to examine EZH2 expression in ESCC lines (YM-1 and KYSE-30) following the separately transfected silencing and ectopic expressional EZH2 vectors in ESCC. Subsequently, expression of miR-200c and EMT markers was also assessed using qRT-PCR, western blotting and immunocytochemistry. Underexpression of Mir200c was detected in YM-1 and KYSE-30 cells after EZH2 silencing, while its overexpression was observed after EZH2 induced expression. Following EZH2 silencing, downregulation of mesenchymal markers and upregulation of epithelial markers were detected in the ESCCs. Our results demonstrate that EZH2 regulates the expression of miR-200c and critical EMT genes, implying that overexpression of Zeb2, Fibronectin, N-cadherin, and Vimentin lead to a mesenchymal phenotype and morphology while underexpression of epithelial genes, enhance cell migration after enforced expression of EZH2 in ESCCs. EZH2 gene can be a beneficial treatment marker for patients with esophageal cancer through decrease invasiveness of the disease and efficient response to neoadjuvant therapy.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / MicroARNs / Transición Epitelial-Mesenquimal / Proteína Potenciadora del Homólogo Zeste 2 / Carcinoma de Células Escamosas de Esófago Límite: Humans Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / MicroARNs / Transición Epitelial-Mesenquimal / Proteína Potenciadora del Homólogo Zeste 2 / Carcinoma de Células Escamosas de Esófago Límite: Humans Idioma: En Revista: Sci Rep Año: 2022 Tipo del documento: Article País de afiliación: Irán